Proton therapy of cancer: Potential clinical advantages and cost-effectiveness

References

• Suit H, Goldberg S, Niemierko A, Trofimov A, Adams J, Paganetti H, et al. Proton beams to replace photon beams in radical dose treatments. Acta Oncol 2003; 42(8)800–8
   PubMed Web of Science ®Google Scholar
• Glimelius B, Isacsson U, Blomquist E, Grusell E, Jung B, Montelius A. Potential gains using high-energy protons for therapy of malignant tumours. Acta Oncol 1999; 38(2)137–45
   PubMed Web of Science ®Google Scholar
• Rutqvist L, Rose C, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in breast cancer. Acta Oncol 2003; 42(5–6)532–545
   PubMed Web of Science ®Google Scholar
• Lomax AJ, Cella L, Weber D, Kurtz JM, Miralbell R. Potential role of intensity-modulated photons and protons in the treatment of the breast and regional nodes. Int J Radiat Oncol Biol Phys 2003; 55(3)785–92
   PubMed Web of Science ®Google Scholar
• Gagliardi G, Lax I, Ottolenghi A, Rutqvist LE. Long-term cardiac mortality after radiotherapy of breast cancer—application of the relative seriality model. Br J Radiol 1996; 69(825)839–46
   PubMedGoogle Scholar
• Gagliardi G, Bjohle J, Lax I, Ottolenghi A, Eriksson F, Liedberg A, et al. Radiation pneumonitis after breast cancer irradiation: analysis of the complication probability using the relative seriality model. Int J Radiat Oncol Biol Phys 2000; 46(2)373–81
   PubMedGoogle Scholar
• Hernberg M, Virkkunen P, Maasilta P, Keyrilainen J, Blomqvist C, Bergh J, et al. Pulmonary toxicity after radiotherapy in primary breast cancer patients: results from a randomized chemotherapy study. Int J Radiat Oncol Biol Phys 2002; 52(1)128–36
   PubMedGoogle Scholar
• Hurkmans CW, Borger JH, Bos LJ, van der Horst A, Pieters BR, Lebesque JV, et al. Cardiac and lung complication probabilities after breast cancer irradiation. Radiother Oncol 2000; 55(2)145–51
   PubMedGoogle Scholar
• Cho KH, Khan FM, Levitt SH. Cost-benefit analysis of 3D conformal radiation therapy—treatment of prostate cancer as a model. Acta Oncol 1999; 38(5)603–11
   PubMedGoogle Scholar
• Tralins K, Wallner K. Follow-up costs after external radiation for low risk prostate cancer. Int J Radiat Oncol Biol Phys 1999; 44(2)323–6
   PubMedGoogle Scholar
• Altwein J, Ekman P, Barry M, Biermann C, Carlsson P, Fossa S, et al. How is quality of life in prostate cancer patients influenced by modern treatment? The Wallenberg Symposium. Urology 1997; 49((4A Suppl))66–76
   PubMedGoogle Scholar
• Fransson P, Damber JE, Tomic R, Modig H, Nyberg G, Widmark A. Quality of life and symptoms in a randomized trial of radiotherapy versus deferred treatment of localized prostate carcinoma. Cancer 2001; 92(12)3111–9
   PubMedGoogle Scholar
• Zelefsky MJ, Cowen D, Fuks Z, Shike M, Burman C, Jackson A, et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 1999; 85(11)2460–8
   PubMed Web of Science ®Google Scholar
• Shipley WU, Verhey LJ, Munzenrider JE, Suit HD, Urie MM, McManus PL, et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 1995; 32(1)3–12
   PubMed Web of Science ®Google Scholar
• Slater JD, Yonemoto LT, Rossi CJ, Jr, Reyes-Molyneux NJ, Bush DA, Antoine JE, et al. Conformal proton therapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 1998; 42(2)299–304
   PubMed Web of Science ®Google Scholar
• Zackrisson B, Mercke C, Strander H, Wennerberg J, Cavallin-Stahl E. A systematic overview of radiation therapy effects in head and neck cancer. Acta Oncol 2003; 42(5–6)443–61
   PubMed Web of Science ®Google Scholar
• Cozzi L, Fogliata A, Lomax A, Bolsi A. A treatment planning comparison of 3D conformal therapy, intensity modulated photon therapy and proton therapy for treatment of advanced head and neck tumours. Radiother Oncol 2001; 61(3)287–97
   PubMedGoogle Scholar
• Freeman CR, Taylor RE, Kortmann RD, Carrie C. Radiotherapy for medulloblastoma in children: a perspective on current international clinical research efforts. Med Pediatr Oncol 2002; 39(2)99–108
   PubMedGoogle Scholar
• Kiltie AE, Lashford LS, Gattamaneni HR. Survival and late effects in medulloblastoma patients treated with craniospinal irradiation under three years old. Med Pediatr Oncol 1997; 28(5)348–54
   PubMedGoogle Scholar
• Miralbell R, Lomax A, Russo M. Potential role of proton therapy in the treatment of pediatric medulloblastoma/primitive neuro-ectodermal tumors: spinal theca irradiation. Int J Radiat Oncol Biol Phys 1997; 38(4)805–11
   PubMed Web of Science ®Google Scholar
• Drummond M, O'Brien B. Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press. Oxford. 1997
   Google Scholar
• Ekman M. Studies in Health Economics. EFI, Stockholm School of Economics, Stockholm 2002
   Google Scholar
• Sonnenberg F, Beck J. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13(4)322–38
   PubMed Web of Science ®Google Scholar
• Statistics Sweden. Sweden's Statistical Databases. 2005.
   Google Scholar
• Goitein M, Jermann M. The relative costs of proton and X-ray radiation therapy. Clin Oncol (R Coll Radiol) 2003; 15(1)S37–50
   PubMed Web of Science ®Google Scholar
• Strålbehandling vid cancer. Linköping:The Swedish Council on Technology Assessment in Health Care (SBU); 2003.
   Google Scholar
• SPTC. Summary report from the project group for the Swedish Proton Therapy Centre (SPTC). 2003.
   Google Scholar
• Pricelist, patient hotel at Akademiska hospital, Uppsala. 2003.
   Google Scholar
• Hurkmans CW, Cho BC, Damen E, Zijp L, Mijnheer BJ. Reduction of cardiac and lung complication probabilities after breast irradiation using conformal radiotherapy with or without intensity modulation. Radiother Oncol 2002; 62(2)163–71
   PubMedGoogle Scholar
• Lind PA, Pagnanelli R, Marks LB, Borges-Neto S, Hu C, Zhou SM, et al. Myocardial perfusion changes in patients irradiated for left-sided breast cancer and correlation with coronary artery distribution. Int J Radiat Oncol Biol Phys 2003; 55(4)914–20
   PubMed Web of Science ®Google Scholar
• Gyenes G, Rutqvist LE, Liedberg A, Fornander T. Long-term cardiac morbidity and mortality in a randomized trial of pre- and postoperative radiation therapy versus surgery alone in primary breast cancer. Radiother Oncol 1998; 48(2)185–90
   PubMed Web of Science ®Google Scholar
• Gyenes G. Radiation-induced ischemic heart disease in breast cancer—a review. Acta Oncol 1998; 37(3)241–6
   PubMed Web of Science ®Google Scholar
• Johansson J, Isacsson U, Lindman H, Montelius A, Glimelius B. Node-positive left-sided breast cancer patients after breast-conserving surgery: potential outcomes of radiotherapy modalities and techniques. Radiother Oncol 2002; 65(2)89–98
   PubMedGoogle Scholar
• Lomax AJ, Boehringer T, Coray A, Egger E, Goitein G, Grossmann M, et al. Intensity modulated proton therapy: a clinical example. Med Phys 2001; 28(3)317–24
   PubMed Web of Science ®Google Scholar
• Lundkvist J, Ekman M, Ericsson Rehn S, Isacsson U, Jönsson B, Glimelius B. Economic evaluation of proton radiation therapy in the treatment of breast cancer. Radiother Oncol 2005; 75(2)179–85
   PubMedGoogle Scholar
• Travis LB. Therapy-associated solid tumors. Acta Oncol 2002; 41(4)323–33
   PubMed Web of Science ®Google Scholar
• Darby S, McGale P, Peto R, Granath F, Hall P, Ekbom A. Mortality from cardiovascular disease more than 10 years after radiotherapy for breast cancer: nationwide cohort study of 90 000 Swedish women. BMJ 2003; 326(7383)256–7
   PubMedGoogle Scholar
• Lind PA, Gagliardi G, Wennberg B, Fornander T. A descriptive study of pulmonary complications after postoperative radiation therapy in node-positive stage II breast cancer. Acta Oncol 1997; 36(5)509–15
   PubMed Web of Science ®Google Scholar
• Zethraeus N, Molin T, Henriksson P, Jonsson B. Costs of coronary heart disease and stroke: the case of Sweden. J Intern Med 1999; 246(2)151–9
   PubMedGoogle Scholar
• National inpatient care statistics. Stockholm:National Board of Health and Welfare (Socialstyrelsen, EpC); 2002
   Google Scholar
• Price list, Lund University hospital, Lund, Sweden. 2002.
   Google Scholar
• LINFO, FASS Lakemedel i Sverige (Swedish drug prices). 2001, Oslo: Lakemedelsinformation AB.
   Google Scholar
• National statistics. Stockholm:Statistic Sweden; 2003
   Google Scholar
• Nicholson T, McGuire A, Milne R. Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease. BMC Cardiovasc Disord 2001; 1(1)2
   PubMedGoogle Scholar
• Capomolla S, Febo O, Ceresa M, Caporotondi A, Guazzotti G, La Rovere M, et al. Cost/utility ratio in chronic heart failure: comparison between heart failure management program delivered by day-hospital and usual care. J Am Coll Cardiol 2002; 40(7)1259–66
   PubMedGoogle Scholar
• Cohen DJ, Taira DA, Berezin R, Cox DA, Morice MC, Stone GW, et al. Cost-effectiveness of coronary stenting in acute myocardial infarction: results from the stent primary angioplasty in myocardial infarction (stent-PAMI) trial. Circulation 2001; 104(25)3039–45
   PubMedGoogle Scholar
• Sandblom G, Dufmats M, Varenhorst E. Long-term survival in a Swedish population-based cohort of men with prostate cancer. Urology 2000; 56(3)442–7
   PubMedGoogle Scholar
• Lilleby W, Fossa SD, Waehre HR, Olsen DR. Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy. Int J Radiat Oncol Biol Phys 1999; 43(4)735–43
   PubMedGoogle Scholar
• Dearnaley DP, Khoo VS, Norman AR, Meyer L, Nahum A, Tait D, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999; 353(9149)267–72
   PubMed Web of Science ®Google Scholar
• Widmark A, Fransson P, Tavelin B. Self-assessment questionnaire for evaluating urinary and intestinal late side effects after pelvic radiotherapy in patients with prostate cancer compared with an age-matched control population. Cancer 1994; 74(9)2520–32
   PubMed Web of Science ®Google Scholar
• Kupelian PA, Reddy CA, Carlson TP, Altsman KA, Willoughby TR. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. Int J Radiat Oncol Biol Phys 2002; 53(4)904–12
   PubMedGoogle Scholar
• Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002; 53(5)1111–6
   PubMed Web of Science ®Google Scholar
• Gardner BG, Zietman AL, Shipley WU, Skowronski UE, McManus P. Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer. J Urol 2002; 167(1)123–6
   PubMedGoogle Scholar
• Stockholm County Council, StockholmSweden. 2003.
   Google Scholar
• Crook J, Esche B, Futter N. Effect of pelvic radiotherapy for prostate cancer on bowel, bladder, and sexual function: the patient's perspective. Urology 1996; 47(3)387–94
   PubMedGoogle Scholar
• Johnstone PA, Gray C, Powell CR. Quality of life in T1-3N0 prostate cancer patients treated with radiation therapy with minimum 10-year follow-up. Int J Radiat Oncol Biol Phys 2000; 46(4)833–8
   PubMedGoogle Scholar
• Price list, Labmedicin, Huddinge hospital, Stockholm. 2003.
   Google Scholar
• Krahn M, Ritvo P, Irvine J, Tomlinson G, Bremner KE, Bezjak A, et al. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med Care 2003; 41(1)153–64
   PubMedGoogle Scholar
• Saigal CS, Gornbein J, Reid K, Litwin MS. Stability of time trade-off utilities for health states associated with the treatment of prostate cancer. Qual Life Res 2002; 11(5)405–14
   PubMed Web of Science ®Google Scholar
• Albertsen PC, Nease RF, Jr, Potosky AL. Assessment of patient preferences among men with prostate cancer. J Urol 1998; 159(1)158–63
   PubMedGoogle Scholar
• Nilsson S, Widmark A, Norlen BJ. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol 2004; 43: 316–81
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatramen ES, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998; 41(3)491–500
   PubMedGoogle Scholar
• Perez CA, Michalski J, Lockett MA. Radiation therapy in the treatment of localized prostate cancer: an alternative to an emerging consensus. Mo Med 1995; 92(11)696–704
   PubMedGoogle Scholar
• Hanks GE, Hanlon AL, Pinover WH, Horwitz EM, Price RA, Schultheiss T. Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys 2000; 46(4)823–32
   PubMedGoogle Scholar
• Pollack A, Hanlon AL, Movsas B, Hanks GE, Uzzo R, Horwitz EM. Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003; 57(1)19–23
   PubMed Web of Science ®Google Scholar
• Cella L, Lomax A, Miralbell R. Potential role of intensity modulated proton beams in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2001; 49(1)217–23
   PubMedGoogle Scholar
• Statistical Yearbook of Sweden. Statistics Sweden 2001.
   Google Scholar
• Mendenhall W, Riggs C, Amdur R, Hinerman R, Villaret D. Altered fractionation and/or adjuvant chemotherapy in definitive irradiation of squamous cell carcinoma of the head and neck. Laryngoscope 2003; 113(3)546–51
   PubMedGoogle Scholar
• Horiot JC, Le Fur R, N'Guyen T, Chenal C, Schraub S, Alfonsi S, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 1992; 25(4)231–41
   PubMedGoogle Scholar
• Fu K, Pajak T, Trotti A, Jones C, Spencer S, Phillips T, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000; 48(1)7–16
   PubMed Web of Science ®Google Scholar
• Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000; 18(7)1458–64
   PubMed Web of Science ®Google Scholar
• Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000; 18(19)3339–45
   PubMed Web of Science ®Google Scholar
• Henson BS, Inglehart MR, Eisbruch A, Ship JA. Preserved salivary output and xerostomia-related quality of life in head and neck cancer patients receiving parotid-sparing radiotherapy. Oral Oncol 2001; 37(1)84–93
   PubMedGoogle Scholar
• Lin A, Kim HM, Terrell JE, Dawson LA, Ship JA, Eisbruch A. Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study. Int J Radiat Oncol Biol Phys 2003; 57(1)61–70
   PubMed Web of Science ®Google Scholar
• Hammerlid E, Silander E, Hornestam L, Sullivan M. Health-related quality of life three years after diagnosis of head and neck cancer—a longitudinal study. Head Neck 2001; 23(2)113–25
   PubMed Web of Science ®Google Scholar
• Hammerlid E, Taft C. Health-related quality of life in long-term head and neck cancer survivors: a comparison with general population norms. Br J Cancer 2001; 84(2)149–56
   PubMed Web of Science ®Google Scholar
• Epstein JB, Emerton S, Kolbinson DA, Le ND, Phillips N, Stevenson-Moore P, et al. Quality of life and oral function following radiotherapy for head and neck cancer. Head Neck 1999; 21(1)1–11
   PubMedGoogle Scholar
• Epstein JB, Robertson M, Emerton S, Phillips N, Stevenson-Moore P. Quality of life and oral function in patients treated with radiation therapy for head and neck cancer. Head Neck 2001; 23(5)389–98
   PubMed Web of Science ®Google Scholar
• Hospital dentist Marta Roing, personal communication. 2003.
   Google Scholar
• Statistical Yearbook of Health and Medical Care. National Board of Health and Welfare 2002.
   Google Scholar
• Lundkvist J, Ekman M, Ericsson SR, Jonsson B, Glimelius B. Cost- effectiveness of proton radiation in the treatment of childhood medulloblastoma. Cancer 2005; 103(4)793–801
   PubMed Web of Science ®Google Scholar
• Mertens AC, Yasui Y, Neglia JP, Potter JD, Nesbit ME, Jr, Ruccione K, et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol 2001; 19(13)3163–72
   PubMed Web of Science ®Google Scholar
• Moller TR, Garwicz S, Barlow L, Falck Winther J, Glattre E, Olafsdottir G, et al. Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. J Clin Oncol 2001; 19(13)3173–81
   PubMed Web of Science ®Google Scholar
• Grau C, Overgaard J. Postirradiation sensorineural hearing loss: a common but ignored late radiation complication. Int J Radiat Oncol Biol Phys 1996; 36(2)515–7
   PubMedGoogle Scholar
• Huang E, Teh BS, Strother DR, Davis QG, Chiu JK, Lu HH, et al. Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys 2002; 52(3)599–605, 3rd
   PubMed Web of Science ®Google Scholar
• Copeland DR, deMoor C, Moore BD, 3rd, Ater JL. Neurocognitive development of children after a cerebellar tumor in infancy: A longitudinal study. J Clin Oncol 1999; 17(11)3476–86
   PubMed Web of Science ®Google Scholar
• Gurney JG, Kadan-Lottick NS, Packer RJ, Neglia JP, Sklar CA, Punyko JA, et al. Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study. Cancer 2003; 97(3)663–73
   PubMed Web of Science ®Google Scholar
• Miralbell R, Lomax A, Cella L, Schneider U. Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Int J Radiat Oncol Biol Phys 2002; 54(3)824–9
   PubMed Web of Science ®Google Scholar
• Ris MD, Packer R, Goldwein J, Jones-Wallace D, Boyett JM. Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study. J Clin Oncol 2001; 19(15)3470–6
   PubMed Web of Science ®Google Scholar
• Palmer SL, Goloubeva O, Reddick WE, Glass JO, Gajjar A, Kun L, et al. Patterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysis. J Clin Oncol 2001; 19(8)2302–8
   PubMed Web of Science ®Google Scholar
• Walter AW, Mulhern RK, Gajjar A, Heideman RL, Reardon D, Sanford RA, et al. Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children's Research Hospital. J Clin Oncol 1999; 17(12)3720–8
   PubMed Web of Science ®Google Scholar
• Ricardi U, Corrias A, Einaudi S, Genitori L, Sandri A, di Montezemolo LC, et al. Thyroid dysfunction as a late effect in childhood medulloblastoma: a comparison of hyperfractionated versus conventionally fractionated craniospinal radiotherapy. Int J Radiat Oncol Biol Phys 2001; 50(5)1287–94
   PubMedGoogle Scholar
• Archambeau JO, Slater JD, Slater JM, Tangeman R. Role for proton beam irradiation in treatment of pediatric CNS malignancies. Int J Radiat Oncol Biol Phys 1992; 22(2)287–94
   PubMedGoogle Scholar
• Mohr PE, Feldman JJ, Dunbar JL. The societal costs of severe to profound hearing loss in the United States. Policy Anal Brief H Ser 2000; 2(1)1–4
   PubMedGoogle Scholar
• Horapparat for vuxna-nytta och kostnader. Linkoping:The Swedish Council on Technology Assessment in Health Care (SBU); 2003
   Google Scholar
• Schwartz J. Societal benefits of reducing lead exposure. Environ Res 1994; 66(1)105–24
   PubMed Web of Science ®Google Scholar
• Läkemedelsboken. Lund:Apoteket AB; 2001
   Google Scholar